Two polygenic mouse models of major depressive disorders identify TMEM161B as a potential biomarker of disease in humans - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Neuropsychopharmacology Year : 2024

Two polygenic mouse models of major depressive disorders identify TMEM161B as a potential biomarker of disease in humans

Marcela Pereira
Anne Wierinckx
  • Function : Author
Wissam El-Hage
Per Svenningsson

Abstract

Treatments are only partially effective in major depressive disorders (MDD) but no biomarker exists to predict symptom improvement in patients. Animal models are essential tools in the development of antidepressant medications, but while recent genetic studies have demonstrated the polygenic contribution to MDD, current models are limited to either mimic the effect of a single gene or environmental factor. We developed in the past a model of depressive-like behaviors in mice (H/Rouen), using selective breeding based on behavioral reaction after an acute mild stress in the tail suspension test. Here, we propose a new mouse model of depression (H-TST) generated from a more complex genetic background and based on the same selection process. We first demonstrated that H/Rouen and H-TST mice had similar phenotypes and were more sensitive to glutamate-related antidepressant medications than selective serotonin reuptake inhibitors. We then conducted an exome sequencing on the two mouse models and showed that they had damaging variants in 174 identical genes, which have also been associated with MDD in humans. Among these genes, we showed a higher expression level of Tmem161b in brain and blood of our two mouse models. Changes in TMEM161B expression level was also observed in blood of MDD patients when compared with controls, and after 8-week treatment with duloxetine, mainly in good responders to treatment. Altogether, our results introduce H/Rouen and H-TST as the two first polygenic animal models of MDD and demonstrate their ability to identify biomarkers of the disease and to develop rapid and effective antidepressant medications.
Embargoed file
Embargoed file
0 3 21
Year Month Jours
Avant la publication
Wednesday, August 7, 2024
Embargoed file
Wednesday, August 7, 2024
Please log in to request access to the document

Dates and versions

inserm-04444848 , version 1 (07-02-2024)

Identifiers

Cite

Malika El Yacoubi, Claire Altersitz, Violaine Latapie, Elari Rizkallah, Sébastien Arthaud, et al.. Two polygenic mouse models of major depressive disorders identify TMEM161B as a potential biomarker of disease in humans. Neuropsychopharmacology, 2024, ⟨10.1038/s41386-024-01811-8⟩. ⟨inserm-04444848⟩
35 View
1 Download

Altmetric

Share

Gmail Facebook X LinkedIn More